Post-earnings recap
Reported
Tue, May 5, 2026
EPS actual
$-0.83
EPS est.
$-0.86
EPS surprise
+3.04%
1-day move
+7.86%
Rhythm Pharmaceuticals reported a smaller loss per share than analysts expected, which contributed to a positive stock reaction, with shares rising by 7.86%. However, the company did not provide revenue figures or any forward guidance, leaving some uncertainty about future performance. Investors may be encouraged by the EPS beat, but the lack of revenue data could lead to cautious sentiment.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.83 | $-0.86 | +3.04% |
| Revenue | — | $56M | — |
No transcript is on record, and the analysis is based on numerical results only.
Rhythm Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for rare genetic disorders that cause obesity. With a market cap of $6 billion, it plays a significant role in the health care sector, particularly in addressing unmet medical needs in obesity treatment.
Last quarter
In the last quarter, Rhythm Pharmaceuticals reported an EPS of $-0.73, which was better than analysts' expectations. However, the stock reacted negatively the following day, indicating market disappointment despite the surprise.
EPS beat streak
3Q
EPS beat rate
50%
Avg EPS surprise
-3.02%
Avg 1-day reaction
+1.73%
Analysts expect Rhythm Pharmaceuticals to report a loss of $-0.86 per share on revenues of $56 million. The market is closely watching for any signs of improved sales or cost management.
Bull case
If the company can exceed revenue expectations and show progress in its product pipeline, it may lead to a positive stock reaction and renewed investor confidence.
Bear case
On the other hand, if the company fails to meet revenue expectations or reports wider losses, it could lead to further declines in stock price, reflecting ongoing concerns about its financial health.
Key metrics to watch
EPS
$-0.86Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.
Revenue
$56MRevenue figures will provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will the revenue exceed the consensus estimate of $56 million?
Revenue performance is critical for assessing the company's market traction and growth potential.
Q2
How will management address the ongoing losses and what plans are in place to improve profitability?
Investors are keen to understand the company's strategy for managing costs and achieving financial stability.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The Street may be underestimating the potential for Rhythm to exceed revenue expectations based on recent product developments and market interest.
Supporting evidence
Options are pricing a move of 11.04%, indicating higher volatility than historical averages.
The company has a history of surprising on EPS, which could lead to a positive reaction if revenue is strong.
Key risk
If revenue comes in above $56 million, it could significantly shift market sentiment.
Pre-commit to what would confirm each case.
This quarter's performance is pivotal as it will reflect the company's ability to navigate financial challenges and capitalize on market opportunities.
Bull confirmed if
A revenue figure above $56 million would confirm the bull case and suggest strong market demand.
Bear confirmed if
A revenue figure below $53 million would confirm the bear case and raise concerns about the company's growth prospects.
What the market is pricing for the move.
Implied Move
±11.04%
Historical Avg
±4.4%
The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.
Options are pricing ±12.8% while RYTM has averaged ±4.4% over the last 8 prints — setup is pricing rich.
ATM IV
0.9%
30d HV
51.1%
Smart-money positioning from the most recent 13F filings.
Institutional
114.84%
of float
Insider
0.70%
of float
Holders
428
institutions
Top Holders· as of Jun 2026
RA Capital Management, L.P.
6,666,837 sh · $589.7M
9.73%
Flat
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Rhythm beats expectations, history suggests the stock could rise by around 1.7%, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.
Miss
A miss could lead to a decline of approximately 2.5%, reflecting ongoing concerns about the company's financial health.
The lines on the call that would change the story.
Blackrock Inc.
6,156,902 sh · $544.6M
8.98%
-1.3%
Baker Bros. Advisors, LP
5,604,483 sh · $495.7M
8.18%
Flat
Primecap Management Company
3,168,853 sh · $280.3M
4.62%
-7.3%
Vanguard Portfolio Management LLC
3,136,895 sh · $277.5M
4.58%
3.2%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.